Phase 1 (Safety and Dosage)

Phase 1 clinical trials aim to evaluate the safety, tolerability, and pharmacokinetics of investigational products, especially in first-in-human (FIH) settings. One of the most critical aspects of early-phase trial design is the implementation of stopping rules and Dose Limiting Toxicity (DLT) criteria. These safety mechanisms ensure that trials are halted or adjusted when adverse events (AEs) suggest that further exposure at a given dose is unethical or potentially harmful.
Click to read the full article.

One of the most important goals of Phase 1 clinical trials is to understand how a new drug behaves in the human body. This is achieved by studying pharmacokinetics (PK) and pharmacodynamics (PD). An effective PK/PD sampling strategy ensures robust data generation to support safety, dose escalation, and future trial design. In this tutorial, we explore what to measure, when to collect samples, and how to align with regulatory and scientific expectations.
Click to read the full article.

Pharmacokinetic (PK) analysis is a fundamental component of Phase 1 clinical trials. It provides insight into how a drug is absorbed, distributed, metabolized, and eliminated in humans. This data is essential for determining safe and effective dosing regimens. In this tutorial, we walk through the complete PK workflow—from sample collection to final reporting—to help clinical researchers, analysts, and sponsors understand how to generate reliable and compliant PK data.
Click to read the full article.

Biomarkers have become a cornerstone of modern drug development, especially in early-phase clinical trials. In Phase 1 studies, where the primary focus is on safety and pharmacokinetics (PK), biomarkers serve as crucial tools to evaluate target engagement, pharmacodynamics (PD), mechanism of action, and even early signs of efficacy. The thoughtful integration of validated, exploratory, and surrogate biomarkers enhances trial design, reduces uncertainty, and accelerates decision-making. This tutorial explores the different types of biomarkers, their application in Phase 1 studies, and how to incorporate them effectively.
Click to read the full article.

Food effect studies are a critical component of Phase 1 clinical development. Understanding how food impacts drug absorption, bioavailability, and pharmacokinetics (PK) allows sponsors to provide dosing recommendations (e.g., “take with food” or “take on an empty stomach”) in product labeling. Regulatory agencies such as the FDA and EMA often require these studies before progressing to Phase 2 or Phase 3 trials. This tutorial explains how food effect studies are designed, executed, and interpreted in early-phase research.
Click to read the full article.

As drug development becomes increasingly global, regulatory authorities are placing greater emphasis on ensuring that clinical trial data are relevant across different ethnic populations. Ethnic bridging studies in Phase 1 help determine whether pharmacokinetic (PK), pharmacodynamic (PD), or safety profiles vary significantly between populations. These studies are essential to support drug approvals and dose recommendations in regions such as Asia, especially Japan, China, and India. This tutorial explores when bridging studies are required, how they’re designed, and how to interpret their outcomes.
Click to read the full article.

Adaptive design is transforming early-phase clinical research by introducing flexibility into traditionally rigid study frameworks. In Phase 1 trials, where decisions must often be made rapidly based on emerging safety or pharmacokinetic (PK) data, adaptive design enables real-time learning and optimization. This tutorial explores the various types of adaptive designs used in Phase 1 studies, their regulatory acceptance, operational considerations, and benefits in accelerating drug development.
Click to read the full article.

While early-phase clinical trials typically involve healthy adult volunteers, Phase 1 studies sometimes need to assess how drugs behave in special populations, including the elderly, patients with renal impairment, and those with hepatic dysfunction. These subgroups are often underrepresented in clinical research, yet they represent a significant portion of real-world drug users. Studying pharmacokinetics (PK), safety, and tolerability in these groups ensures optimal dosing and informs labeling for safe use. This article explores the rationale, design, and regulatory framework for including special populations in Phase 1 trials.
Click to read the full article.

Drug-drug interactions (DDIs) represent a major challenge in clinical pharmacology, especially during the early development phase. In Phase 1 trials, understanding how a new investigational product (IP) behaves when co-administered with other commonly used medications is crucial for patient safety and dose optimization. DDI studies identify whether a drug is a perpetrator (causing an interaction) or a victim (affected by another drug). This tutorial outlines the essential components of DDI study design in Phase 1, including regulatory guidance, PK/PD endpoints, selection of probe substrates, and data interpretation.
Click to read the full article.

Phase 1 clinical trials in oncology differ significantly from those in other therapeutic areas. Unlike traditional Phase 1 studies conducted in healthy volunteers, oncology trials are usually initiated directly in patients with advanced cancers. These trials aim not only to assess safety and pharmacokinetics (PK), but also to explore early signs of efficacy, dose-response, and biomarker correlations. With the rise of immunotherapies, targeted agents, and biologics, designing and executing early-phase oncology trials has become more complex and strategically critical to success in later phases.
Click to read the full article.